Approach — Thelamux

Structure

How the Platform Works

Three integrated functions operating as one system.

Platform

Thelamux

The central platform responsible for sourcing, in-licensing, strategy, and capital allocation — guiding pipeline expansion and platform-level decision-making.

A discovery engine for originating novel compounds through hypothesis-driven design, translational science, and capital-efficient preclinical validation leveraging external research infrastructure.

A focused development unit advancing assets through milestone-driven clinical execution with clear ownership, defined inflection points, and disciplined capital deployment.

The insight

Biotech is a capital allocation problem.

Single-asset companies carry binary risk. Capital is committed before a program is validated. Infrastructure and learning are rebuilt every time, by every company, from scratch.

The economics are broken — and execution alone cannot fix them. Thelamux is designed to fix the economics first.

The economics gap

Traditional single-asset biotechs are slower and more capital-intensive than they need to be.

A platform-built Telanode reaches the same clinical inflection on shared infrastructure — faster, leaner, and with portfolio-level learning.

The opportunity

Precision medicine enables faster, more targeted development.

Oncology, hematology, and rare disease are the fastest-growing therapeutic areas — with biomarker-defined populations expanding and accelerated regulatory pathways available. The platform model captures this opportunity systematically.

Sourcing

Disciplined selection.

Asset selection aligned with platform strategy — license or acquire globally through clinical and institutional networks.

Activation

Shared infrastructure.

Each Telanode plugs into the THELA + MUX operating system on day one — clinical, regulatory, CMC, translational — inherited, not rebuilt.

Scale

Parallel development.

Multiple programs run in parallel without proportional cost increases. Portfolio-level learning compounds across every Telanode.

The model

Discover. Identify. Advance. Realize.

One repeatable cycle. Applied first to Tethra. Designed to scale to every Telanode that follows.

01

Pipeline Expansion

Source and expand the pipeline through disciplined asset selection, in-licensing, and selective discovery aligned with platform strategy.

02

Rapidly Advance

Drive each asset to clinical inflection (Phase 1/2) on shared MUX infrastructure — biology-driven cohort design, accelerated execution.

03

Multi-Shots on Goal

Expand across indications and biomarker cohorts. Multiple independent paths to clinical signal per asset.

04

Commercialize or Exit

Realize value at inflection — commercialize directly, partner, or exit through M&A or IPO. Optionality is structural, not pre-committed.

The architecture

THELA decides. MUX executes. Telanodes deliver.

A two-engine operating system that compounds across every asset the platform owns.

THELA

Strategic intelligence engine.

Portfolio prioritization. Capital allocation against milestone gates. Asset-level risk management. Cross-Telanode learning loops.

MUX

Centralized execution engine.

Clinical operations. Regulatory and CMC. CRO and vendor management. Data, analytics, and translational platform — built once, leveraged across every Telanode.

Telanodes are the operating subsidiaries — the asset entities the platform builds, owns, and capitalizes. Every Telanode runs on the same THELA + MUX stack from day one.

Capital efficiency

More clinical progress per dollar deployed.

Shared infrastructure changes the unit economics of biotech. The same milestone reached at a fraction of the cost — every time the platform runs a program.

Single-asset biotech

Standalone economics.

· $30–50M annual burn per program
· Duplicated infrastructure built every time
· Standalone clinical, regulatory, CMC teams
· No cross-program learning
· 18–36 months to clinical inflection

Thelamux platform

Shared, compounding economics.

· $5–8M to first clinical signal per Telanode
· Shared MUX infrastructure across every Telanode
· Centralized regulatory, CMC, and ops
· Each program improves the next one
· Under 10 months to clinical inflection

Estimated 50–60% lower cost-to-clinical-proof at platform scale.

The flywheel

Every Telanode makes the next one cheaper, faster, and more likely to succeed.

Assets generate clinical and translational data. Data sharpens THELA's allocation decisions. Decisions compound MUX's execution playbook. Infrastructure lowers cost and time for the next asset — and the cycle compounds.

Single-asset biotechs cannot compound. Platforms can.

Strategic focus

Where the platform plays.

Oncology, hematology, and rare disease — the fastest-growing, highest-conviction segments in U.S. biotech.

Capital is back

$102B

Annual biotech funding rebounded from $61B in 2022 to $102B by 2024 — capital is rotating back into clinical-stage development.

Biotechs drive the pipeline

~67%

Roughly two-thirds of novel FDA approvals in 2024 originated from biotechs — increasingly self-commercializing.

Rare disease compounding

$490B

Rare disease TAM growing at 9%+ CAGR through 2032 — oncology the largest therapy area in the rare category.

A repeatable engine for clinical-stage biotech.